Moderate

AIDS-related Kaposi sarcoma (KS)

HIV malignancy · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

HHV-8 (KSHV)-driven vascular tumour; AIDS-defining. Cutaneous disease is most common (lower limbs, face/nose, oral mucosa, genitalia) but it can involve oral cavity, GI tract and lungs. Incidence is highest in the first 6 months of ART (IRIS unmasking). ED role: recognise, biopsy to exclude mimics, avoid steroids, start/continue ART, manage complications.

Red flags

  • Haemoptysis / dyspnoea / respiratory failure (pulmonary KS)
  • GI bleeding, obstruction or severe abdominal pain
  • Airway-threatening oral/laryngeal lesions
  • Rapidly progressive or atypical lesions (exclude bacillary angiomatosis)
  • KICS features: fever, oedema, high tumour burden (poor prognosis)

Assessment

Differential diagnosis

  • Bacillary angiomatosis (Bartonella - treatable; must exclude)
  • Purpura/haematoma
  • Angioma / pyogenic granuloma
  • Dermatofibroma / naevi
  • Extrapulmonary P. jirovecii (can mimic KS)
  • Cutaneous lymphoma / melanoma

Investigations

  • Skin biopsy to confirm (essential for atypical or rapidly progressive lesions to exclude bacillary angiomatosis)
  • CD4 count + HIV viral load
  • FBC
  • If respiratory symptoms: CXR (nodular/interstitial infiltrates, effusion, hilar/mediastinal adenopathy)
  • If GI symptoms: refer for endoscopy (hemorrhagic nodules)
  • Assess for visceral involvement (oral, GI, pulmonary)

Management

  • Recognise violaceous/pink-red-purple-brown non-blanching lesions, often elliptical along skin tension lines
  • Biopsy to confirm and exclude bacillary angiomatosis (curable)
  • Assess for visceral disease (oral cavity, GI, lungs)
  • Avoid systemic corticosteroids - they induce/exacerbate KS
  • Start/optimise ART (cornerstone of treatment)
  • Refer oncology for staging and systemic chemotherapy if advanced/visceral/pulmonary
  • Treat complications (bleeding, airway compromise, lymphoedema)

Drugs & doses

Antiretroviral therapy (ART) is the cornerstone - start/optimise via HIV team
AVOID systemic corticosteroids - associated with KS induction/exacerbation
Systemic chemotherapy (e.g. liposomal anthracyclines, paclitaxel) for advanced/visceral/pulmonary KS - oncology-directed, NOT ED-initiated (specific regimens/doses are in the KS staging & treatment topic, not this source)
If bacillary angiomatosis cannot be excluded, treat empirically for Bartonella pending biopsy (specialist; agent not specified in source)

Disposition

Most cutaneous KS -> outpatient HIV/oncology referral + ART. Admit for pulmonary KS with respiratory compromise, GI bleeding, airway threat, or KICS.

Complications & pitfalls

  • Pulmonary KS (respiratory failure, haemoptysis)
  • GI bleeding / obstruction
  • Disfiguring lymphoedema
  • KSHV inflammatory cytokine syndrome (KICS; median survival ~13.6 months)
  • IRIS flare in first 6 months of ART
  • Secondary infection of ulcerated lesions

Exam pearls

  • Always biopsy atypical/rapidly-progressive lesions to exclude Bartonella bacillary angiomatosis (curable with antibiotics)
  • Corticosteroids and opportunistic infections can trigger/worsen KS - avoid steroids
  • KS can flare within the first 6 months of ART (IRIS)
  • Visceral disease (oral/GI/lung) is often asymptomatic initially

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.